Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study. International journal of epidemiology Abrahao, R., Huynh, J. C., Benjamin, D. J., Li, Q. W., Winestone, L. E., Muffly, L., Keegan, T. H. 2021; 50 (2): 663-674


BACKGROUND: Curative-intent treatment of acute myeloid leukaemia (AML) can lead to multiple chronic medical conditions ('late effects'). Little is known about the burden of late effects in adolescent and young adult (AYA, 15-39years) survivors of AML. We aimed to estimate the cumulative incidence and investigate the main predictors of late effects among these patients.METHODS: During 1996-2012, 1168 eligible AYAs with AML who survived =2years after diagnosis were identified in the California Cancer Registry. Late effects were reported from State hospital discharge data, and patients were followed through 2014. Hazard ratios and 95% confidence intervals of late effects occurrence were estimated using Cox proportional hazard models, adjusted for sociodemographic and clinical factors.RESULTS: The most common late effects at 10years after diagnosis were: endocrine (26.1%), cardiovascular (18.6%) and respiratory (6.6%), followed by neurologic (4.9%), liver/pancreatic (4.3%), renal (3.1%), avascular necrosis (2.7%) and second primary malignancies (2.4%). Of 1168 survivors, 547 (46.8%) received a haematopoietic stem cell transplant (HSCT). After multivariable adjustments, AYAs who underwent HSCT or had a non-favourable risk AML experienced 2-fold or higher increased likelihood of all late effects. Additionally, AYAs of Hispanic, Black or Asian/Pacific Islander (vs non-Hispanic White) race/ethnicity and those who resided in lower socio-economic neighbourhoods were at higher risk of numerous late effects.CONCLUSIONS: Our findings underscore the need for long-term surveillance for the prevention, early detection and treatment of late effects, and can inform the development of AYA-focused consensus-based guidelines that will ultimately improve the quality of life and survival of these young vulnerable patients.

View details for DOI 10.1093/ije/dyaa184

View details for PubMedID 34000732